NO20015931L - Farmasöytiske formuleringer og fremgangsmåter som omfatter intranasal morfin - Google Patents

Farmasöytiske formuleringer og fremgangsmåter som omfatter intranasal morfin

Info

Publication number
NO20015931L
NO20015931L NO20015931A NO20015931A NO20015931L NO 20015931 L NO20015931 L NO 20015931L NO 20015931 A NO20015931 A NO 20015931A NO 20015931 A NO20015931 A NO 20015931A NO 20015931 L NO20015931 L NO 20015931L
Authority
NO
Norway
Prior art keywords
morphine
methods
pharmaceutically acceptable
acceptable salt
pharmaceutical formulations
Prior art date
Application number
NO20015931A
Other languages
English (en)
Norwegian (no)
Other versions
NO20015931D0 (no
Inventor
Charanjit R Behl
Raja G Achari
Jorge C Demeireles
Ramneik Dua
Vincent D Romeo
Anthony P Sileno
Original Assignee
Nastech Pharm Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nastech Pharm Co filed Critical Nastech Pharm Co
Publication of NO20015931D0 publication Critical patent/NO20015931D0/no
Publication of NO20015931L publication Critical patent/NO20015931L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO20015931A 1999-06-16 2001-12-04 Farmasöytiske formuleringer og fremgangsmåter som omfatter intranasal morfin NO20015931L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33453799A 1999-06-16 1999-06-16
PCT/US2000/014157 WO2000076506A1 (en) 1999-06-16 2000-05-23 Pharmaceutical formulations and methods comprising intranasal morphine

Publications (2)

Publication Number Publication Date
NO20015931D0 NO20015931D0 (no) 2001-12-04
NO20015931L true NO20015931L (no) 2002-02-08

Family

ID=23307687

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20015931A NO20015931L (no) 1999-06-16 2001-12-04 Farmasöytiske formuleringer og fremgangsmåter som omfatter intranasal morfin

Country Status (30)

Country Link
US (1) US6677346B1 (lt)
EP (2) EP1183027A4 (lt)
JP (1) JP2003501467A (lt)
KR (1) KR20020016831A (lt)
AU (1) AU774175B2 (lt)
BG (1) BG106221A (lt)
BR (1) BR0012082A (lt)
CA (1) CA2374877C (lt)
CZ (1) CZ20014399A3 (lt)
DE (1) DE10084709T1 (lt)
DK (1) DK200101859A (lt)
EE (1) EE200100677A (lt)
ES (1) ES2197792B1 (lt)
FI (1) FI20012462L (lt)
GB (1) GB2367005A (lt)
HR (1) HRP20010926A2 (lt)
HU (1) HUP0201856A3 (lt)
IS (1) IS6202A (lt)
LT (1) LT4976B (lt)
LU (1) LU90859B1 (lt)
LV (1) LV12859B (lt)
MX (1) MXPA01012879A (lt)
NO (1) NO20015931L (lt)
NZ (1) NZ515783A (lt)
PL (1) PL352556A1 (lt)
SE (1) SE0104203D0 (lt)
SI (1) SI20850A (lt)
SK (1) SK18172001A3 (lt)
TR (1) TR200103613T2 (lt)
WO (1) WO2000076506A1 (lt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9924797D0 (en) 1999-10-20 1999-12-22 West Pharm Serv Drug Res Ltd Compound
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
US20060083691A1 (en) * 2000-05-10 2006-04-20 Wermeling Daniel P Intranasal opioid compositions, delivery devices and methods of using same
CA2423354C (en) * 2000-09-20 2009-12-15 Lee Shahinian Jr. Self-preserved nasal, inhalable, and topical ophthalmic preparations and medications
EP1418862A4 (en) * 2001-06-29 2010-06-09 Leon J Lewandowski INDIVIDUALIZED SEARCH THERAPY
GB0210264D0 (en) * 2002-05-03 2002-06-12 Arakis Ltd The treatment of pain and migraine headache
US20040102476A1 (en) * 2002-11-25 2004-05-27 Chan Tai Wah High concentration formulations of opioids and opioid derivatives
US20050175679A1 (en) * 2004-02-10 2005-08-11 Michael Moshman Controlled release formulations
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
DK2486942T3 (en) 2004-11-24 2019-01-28 Meda Pharmaceuticals Inc COMPOSITIONS CONTAINING AZELASTINE AND PROCEDURES FOR USING IT
US9415034B2 (en) * 2005-01-05 2016-08-16 National Defense Medical Center Inhibitors and enhancers of uridine diphosphate-glucuronosyltransferase 2B (UGT2B)
ES2277743B2 (es) * 2005-06-02 2008-12-16 Universidade De Santiago De Compostela Nanoparticulas que comprenden quitosano y ciclodextrina.
WO2007025286A2 (en) * 2005-08-26 2007-03-01 The Board Of Trustees Of The Leland Stanford Junior University Therapy procedure for drug delivery for trigeminal pain
US20070212307A1 (en) * 2006-02-10 2007-09-13 Daniel Wermeling Pharmaceutical Compositions Comprising an Opioid Receptor Antagonist and Methods of Using Same
US8226949B2 (en) 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
WO2008077712A1 (en) * 2006-12-22 2008-07-03 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Gel useful for the delivery of ophthalmic drugs
GB2477545B (en) * 2010-02-05 2011-12-21 Special Products Ltd A liquid morphine composition for buccal administration
DK2706982T4 (da) 2011-05-13 2021-05-10 Euro Celtique Sa Intranasale farmaceutiske dosisformer omfattende naloxon
AU2012386221A1 (en) 2012-07-26 2015-02-26 Wockhardt Limited Pharmaceutical composition comprising diamorphine for intranasal administration
EP3082817A4 (en) * 2013-12-18 2017-06-21 Aegis Therapeutics, LLC Compositions for drug administration
US11135155B2 (en) 2014-07-08 2021-10-05 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US11389473B2 (en) 2015-01-07 2022-07-19 Tonix Pharmaceuticals Holding Corp. Magnesium-containing oxytocin formulations and methods of use
MX2018012351A (es) 2016-04-12 2019-02-07 Trigemina Inc Formulaciones de oxitocina que contienen magnesio y metodos de uso.
AU2017345767A1 (en) * 2016-10-21 2019-05-16 Somniferum Labs LLC Apparatus for controlled delivery of opioid and other medications
MA50394A (fr) * 2017-10-20 2021-04-28 Chiesi Farm Spa Formulations pharmaceutiques comprenant un agoniste de récepteur d'opioïde en tant que substances actives, leurs procédés de fabrication et leurs utilisations thérapeutiques
EA202091615A1 (ru) 2018-12-21 2021-03-05 Аегис Терапьютикс, Ллс Интраназальные составы на основе эпинефрина и способы лечения заболевания
CN115804754A (zh) * 2022-12-16 2023-03-17 广州新济药业科技有限公司 吗啡鼻喷剂及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464378A (en) 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4464376A (en) 1982-07-22 1984-08-07 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same
GB8514665D0 (en) * 1985-06-11 1985-07-10 Eroceltique Sa Oral pharmaceutical composition
US5202128A (en) 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
GB9202464D0 (en) * 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
DE69434304T2 (de) * 1993-03-26 2005-12-29 Merkus, Franciscus Wilhelmus H.M. Pharmazeutische Zusammensetzungen zur intranasalen Verabreichung von Dihydroergotamin
GB9426102D0 (en) 1994-12-23 1995-02-22 Merck Sharp & Dohme Pharmacuetical compositions
US5874450A (en) * 1996-09-27 1999-02-23 Nastech Pharmaceutical Company, Inc. Intranasal formulations for promoting sleep and method of using the same

Also Published As

Publication number Publication date
EP1419774A1 (en) 2004-05-19
LT2001119A (lt) 2002-07-25
SE0104203L (sv) 2001-12-14
FI20012462A7 (fi) 2002-01-16
BG106221A (bg) 2002-08-30
HUP0201856A3 (en) 2004-12-28
GB2367005A (en) 2002-03-27
TR200103613T2 (tr) 2004-08-23
CA2374877C (en) 2004-04-13
HUP0201856A1 (en) 2002-09-28
PL352556A1 (en) 2003-08-25
SE0104203D0 (sv) 2001-12-14
DE10084709T1 (de) 2002-09-26
KR20020016831A (ko) 2002-03-06
EP1183027A1 (en) 2002-03-06
SI20850A (sl) 2002-10-31
LU90859B1 (en) 2002-01-24
CZ20014399A3 (cs) 2002-06-12
DK200101859A (da) 2001-12-12
NZ515783A (en) 2004-05-28
BR0012082A (pt) 2002-05-07
JP2003501467A (ja) 2003-01-14
CA2374877A1 (en) 2000-12-21
ES2197792A1 (es) 2004-01-01
ES2197792B1 (es) 2005-05-01
WO2000076506A1 (en) 2000-12-21
AU774175B2 (en) 2004-06-17
IS6202A (is) 2001-12-14
AU5156100A (en) 2001-01-02
NO20015931D0 (no) 2001-12-04
FI20012462L (fi) 2002-01-16
SK18172001A3 (sk) 2002-07-02
LT4976B (lt) 2002-12-30
EP1183027A4 (en) 2003-02-05
EE200100677A (et) 2003-02-17
HRP20010926A2 (en) 2003-04-30
US6677346B1 (en) 2004-01-13
LV12859B (en) 2002-12-20
GB0128383D0 (en) 2002-01-16
MXPA01012879A (es) 2003-06-24

Similar Documents

Publication Publication Date Title
GB2367005A (en) Pharmaceutical formulations and methods comprising intranasal morphine
WO2002042462A3 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
WO2000021515A3 (en) Intranasal codeine for the rapid suppression of cough and rapid relief of pain
NO20040968L (no) Opioidagonistpreparater med frigjorbar og sekvestrert antagonist
ATE247461T1 (de) Formulierung zur intranasalen verabreichung
EP1033998A4 (en) METHOD FOR SUPPRESSING BETA AMYLOID-RELATED CHANGES IN ALZHEIMER
AU3846901A (en) Oral, nasal and pulmonary dosage formualtions of copolymer 1
MXPA01012882A (es) Composiciones y metodos que comprenden gluconato de morfina.
DE69824313D1 (de) Sibutramin und orlistat enthaltende pharmazeutische zusammensetzungen
MXPA01008993A (es) Tratamiento de combinacion para depresion y ansiedad.
ATE311928T1 (de) (-)-pseudoephedrin als sympathomimetisches arzneimittel
NO20042758L (no) Fremgangsmate for behandling av en pasient som krever analgesi.
TW200633694A (en) Composition and method for treating asthma
BR0011880A (pt) Método para o tratamento de condições co-mórbidas associadas com obesidade, composto, produto, uso de um composto, e, composição farmacêutica
TW200700075A (en) Roflumilast and integrin inhibitor combination and method of treatment
MY131159A (en) New pharmaceutical compositions containing epinastine and pseudoephedrine
SE0002354D0 (sv) New formulation
GB2635282A8 (en) An oral liquid formulation of apixaban
MY133957A (en) "compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor"
AU2001295839A1 (en) Use of agents active against candida in the treatment of disorders of the oral and intestinal mucosa
EE200300555A (et) Morfiini sisaldav farmatseutiline preparaat ninasiseseks manustamiseks ning meetod valuvaigistava või tuimastava reaktsiooni esilekutsumiseks imetajal
WO2001035946A3 (en) Intranasal administration of raloxifene and tamoxifen
EP1095655A3 (en) NK-1 receptor antagonists and eletriptan for the treatment of migraine

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application